<DOC>
	<DOCNO>NCT02477644</DOCNO>
	<brief_summary>Randomized , Double-Blind , Phase III Trial Olaparib v . Placebo Patients Advanced FIGO Stage IIIB - IV High Grade Serous Endometrioid Ovarian , Fallopian Tube , Peritoneal Cancer treat standard First-Line Treatment , Combining Platinum-Taxane Chemotherapy Bevacizumab Concurrent Chemotherapy Maintenance .</brief_summary>
	<brief_title>Platine , Avastin OLAparib 1st Line</brief_title>
	<detailed_description>Patients advance FIGO stage IIIB - IV high grade serous endometrioid ovarian , fallopian tube , peritoneal cancer treat standard first-line treatment , combine platinum-taxane chemotherapy bevacizumab concurrent chemotherapy maintenance .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>I1 . Female Patient must ≥18 year age . I2 . Signed informed consent ability comply treatment followup . I3 . Patient newly diagnose I31 Ovarian cancer , primary peritoneal cancer and/or fallopiantube cancer , I32 Histologically confirm ( base local histopathological finding ) : high grade serous high grade endometrioid epithelial non mucinous ovarian cancer patient germline BRCA 1 2 deleterious mutation I33 advance stage : FIGO stage IIIB , IIIC , IV 1988 FIGO classification . I4 . Patient complete prior randomization first line platinumtaxane chemotherapy : 1 . Platinumtaxane base regimen must consist minimum 6 treatment cycle maximum 9 . However platinum base therapy must discontinue early result non hematological toxicity specifically related platinum regimen , ( i.e . neurotoxicity , hypersensitivity etc . ) , patient must receive minimum 4 cycle platinum regimen . 2 . Intravenous , intraperitoneal , neoadjuvant platinum base chemotherapy allow ; weekly therapy , three week consider one cycle . Interval debulking allow . I5 . Patient must receive prior randomization minimum 3 cycle bevacizumab combination 3 last cycle platinumbased chemotherapy . Only case interval debulking surgery , allow realize 2 cycle bevacizumab combination last 3 cycle platiniumbased chemotherapy . Bevacizumab treatment administer dose 15mg/kg q3 week total 15 month . I6 . Patient must prior randomization without evidence disease ( NED ) complete response ( CR ) partial response ( PR ) first line treatment . There clinical evidence disease progression ( physical exam , imagery , CA 125 ) throughout first line treatment prior study randomization . I7 . Patient must randomize least 3 week 9 week last dose chemotherapy ( last dose day last infusion ) major toxicity previous chemotherapy must resolve CTC AE grade 1 good ( except alopecia peripheral neuropathy ) . I8 . Patient must normal organ bone marrow function : 1 . Hemoglobin ≥ 10.0 g/dL . 2 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L . 3 . Platelet count ≥ 100 x 109/L . 4 . Total bilirubin ≤ 1.5 x institutional upper limit normal ( ULN ) . 5 . Aspartate aminotransferase /Serum Glutamic Oxaloacetic Transaminase ( ASAT/SGOT ) ) Alanine aminotransferase /Serum Glutamic Pyruvate Transaminase ( ALAT/SGPT ) ) ≤ 2.5 x ULN , unless liver metastasis present case must ≤ 5 x ULN . 6 . Serum creatinine ≤ 1.25 x institutional ULN creatinine clearance &gt; 50 mL/min . 7 . Patient receive anticoagulant medication International Normalized Ratio ( INR ) ≤1.5 Activated ProThrombin Time ( aPTT ) ≤1.5 x ULN . The use fulldose oral parenteral anticoagulant permit long INR APTT within therapeutic limit ( accord site medical standard ) . If patient oral anticoagulant , dose stable least two week time randomization . 8 . Urine dipstick proteinuria &lt; 2+ . If urine dipstick ≥2+ , 24hour urine must demonstrate &lt; 1 g protein 24 hour . 9 . Normal blood pressure adequately treat controlled hypertension ( systolic BP ≤ 140 mmHg and/or diastolic BP ≤ 90 mmHg ) . I9 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . I10 . Formalin fix , paraffin embed ( FFPE ) tumor sample primary cancer must available central BRCA test test result must available stratification . I11 . Postmenopausal evidence nonchildbearing status woman childbearing potential prior first dose study treatment . ( see appendix 4 ) I12 . For France : In France , subject eligible randomization study either affiliate , beneficiary , social security category . E1 . Nonepithelial origin ovary , fallopian tube peritoneum ( i.e . germ cell tumor ) . E2 . Ovarian tumor low malignant potential ( e.g . borderline tumor ) , mucinous carcinoma . E3 . Patient synchronous primary endometrial cancer unless follow criterion meet : 1. stage &lt; II , 2 . Less 60 year old time diagnosis endometrial cancer stage IA IB grade 1 2 , stage IA grade III endometrioid adenocarcinoma OR ≥ 60 year old time diagnosis endometrial cancer stage IA grade 1 2 endometrioid adenocarcinoma . Patient serous clear cell adenocarcinoma carcinosarcoma endometrium eligible . E4 . Other malignancy within last 5 year except : adequately treat nonmelanoma skin cancer curatively treat situ cancer cervix , ductal carcinoma situ ( DCIS ) . Patient history localize malignancy diagnose 5 year ago may eligible provide complete adjuvant systemic therapy prior randomization patient remain free recurrent metastatic disease . Patient history primary triple negative breast cancer may eligible provide complete definitive anticancer treatment 3 year ago remain breast cancer disease free prior start study treatment . E5 . Patient myelodysplastic syndrome/acute myeloid leukemia history E6 . Patient experience least one cycle , delay &gt; 2 week due prolong hematological recovery first line chemotherapy E7 . Patient receive radiotherapy within 6 week prior study treatment E8 . Major surgery within 4 week start study treatment patient must recover effect major surgery E9 . Previous allergenic bone marrow transplant . E10 . Any previous treatment PARP inhibitor , include olaparib . E11 . Administration simultaneous chemotherapy drug , anticancer therapy antineoplastic hormonal therapy , simultaneous radiotherapy trial treatment period ( hormonal replacement therapy permit steroidal antiemetic ) . E12 . Current recent ( within 10 day prior randomization ) chronic use aspirin &gt; 325 mg/day . E13 . Concomitant use know potent CYP3A4 inhibitor ketoconazole , itraconazole , ritonavir , indinavir , saquinavir , telithromycin , clarithromycin nelfinavir . E14 . Prior history hypertensive crisis ( CTCAE grade 4 ) hypertensive encephalopathy . E15 . Clinically significant ( e.g . active ) cardiovascular disease , include : 1 . Myocardial infarction unstable angina within ≤ 6 month randomization , 2 . New York Heart Association ( NYHA ) ≥ grade 2congestive heart failure ( CHF ) . 3 . Poorly control cardiac arrhythmia despite medication ( patient rate control atrial fibrillation eligible ) , clinically significant abnormal find rest ECG , 4 . Peripheral vascular disease grade ≥ 3 ( e.g . symptomatic interfering activity daily live [ ADL ] require repair revision ) . E16 . Previous CerebroVascular Accident ( CVA ) , Transient Ischemic Attack ( TIA ) Sub Arachnoids Hemorrhage ( SAH ) within 6 month prior randomization . E17 . History evidence hemorrhagic disorder within 6 month prior randomization . E18 . Evidence bleed diathesis significant coagulopathy ( absence coagulation ) . E19 . History clinical suspicion brain metastasis spinal cord compression . CT/MRI brain mandatory ( within 4 week prior randomization ) case suspect brain metastasis . Spinal MRI mandatory ( within 4 week prior randomization ) case suspect spinal cord compression . E20 . History evidence upon neurological examination central nervous system ( CNS ) disease , unless adequately treat standard medical therapy ( e.g . uncontrolled seizure ) . E21 . Significant traumatic injury 4 week prior randomization . E22 . Nonhealing wound , active ulcer bone fracture . Patient granulate incision heal secondary intention evidence facial dehiscence infection eligible require 3 weekly wound examination . E23 . History VEGF therapy relate abdominal fistula gastrointestinal perforation active gastrointestinal bleeding within 6 month prior first study treatment . E24 . Current , clinically relevant bowel obstruction , include subocclusive disease , relate underlying disease . E25 . Patient evidence abdominal free air explain paracentesis recent surgical procedure . E26 . Evidence disease , metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put patient high risk treatment related complication . E27 . Pregnant lactate woman . E28 . Participation another clinical study investigational product chemotherapy course immediately prior randomization . E29 . Patient unable swallow orally administer medication patient gastrointestinal disorder likely interfere absorption study medication . E30 . Patient known hypersensitivity olaparib recipient product . E31 . Immunocompromised patient , e.g. , know active hepatitis ( i.e . Hepatitis B C ) due risk transmit infection blood body fluids patient know serologically positive human immunodeficiency virus ( HIV ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Advanced FIGO IIIB</keyword>
	<keyword>IV high grade serious ovarian cancer</keyword>
	<keyword>endometrioid ovarian cancer</keyword>
	<keyword>standard first-line treatment</keyword>
	<keyword>platinum-taxane chemotherapy</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>olaparib</keyword>
	<keyword>placebo</keyword>
</DOC>